Hawthorn

European Pharmacopoeia sets minimum total flavonoid content for Crataegi folium cum flore (dried flowering tops) at 1.5%, expressed as hyperoside on the dried herb. Aqueous extract minimum is 2.5% total flavonoid. Hydroalcoholic extract minimum is 6% total flavonoid — that is the regulatory ladder. WS 1442 — the most-studied industrial extract, used in Schwabe's Crataegutt® novo — sits at DER 4–6.6:1, standardised to 17.3–20.1% oligomeric procyanidins (Am J Cardiovasc Drugs 2017). Tea-grade dried berries don't typically carry standardised flavonoid claims; moisture and microbiology become the primary spec.

EMA HMPC monograph status is traditional-use, with the indication 'heart complaints related to nervousness, mild symptoms of mental stress, and to aid sleep' — not heart-failure cure. The 2025 EMA draft revision (consultation April–July 2025) extended the scope to include Crataegus pentagyna + Crataegus azarolus alongside the existing monogyna/laevigata/hybrid coverage. The well-established-use NYHA II authorisation for WS 1442 exists in Germany and Austria at the national level — it is not a centralised EMA approval. Downstream marketing claims of 'EMA-approved heart failure treatment' overstate the EU-central regulatory position. The Cochrane 2008 meta-analysis showed exercise tolerance and symptomatic benefit; the SPICE trial (n=2,681, NYHA II–III, 24 months) did NOT show mortality benefit on its composite primary endpoint.

Phytomedicine source geographies are documented as Albania, Bulgaria, Romania, the former Yugoslavia, and Poland. FairWild Foundation lists hawthorn as certifiable; however, FairWild operator status should be verified by company name against the registry rather than assumed by region — the publicly listed FairWild-certified hawthorn operator on the registry (Phytopharm-trade) is based in Ukraine, not Bulgaria. Romanian Carpathian wild collection is documented in agricultural and ethnobotanical literature; the EU-Organic Wild Collection certificate identifier should be disclosed on the COA. For buyers requiring single-source traceable cultivated lots, small-batch Romanian farm-direct material is the alternative posture against the Polish base supply.

European Pharmacopoeia and EMA HMPC monograph cover Crataegus monogyna Jacq. (Lindm.), Crataegus laevigata (Poir.) DC., and their hybrids — together. Specifications that insist on single-species C. monogyna purity are operating outside the regulatory framework that defines the active material. Two red-flag items: (1) 'Crataegus oxyacantha' is taxonomically rejected — it is now consolidated under C. laevigata, but the old name still ships on some B2B catalogues. A COA naming oxyacantha is a supplier-side QC quality signal. (2) Crataegus pinnatifida — Chinese hawthorn used in TCM — sits OUTSIDE the European Ph. Eur. monograph. Material under 'hawthorn berry' labelling from Chinese origin is not pharmacopoeial-grade European hawthorn.

Crataegi folium cum flore (the flowering tops, leaf + flower together) has a narrow 2–3 week harvest window in May–June. For an H2 2026 procurement engagement the 2026 flowering-tops harvest is already in — allocation is against residual 2026 stock or 2027 forward contract. Crataegi fructus (the berry) has a much longer September–November harvest window, with berries sweetening after first frost. The 2026 berry crop opens against the same procurement cycle in which this guide is published. For organic-certified pharmaceutical-grade allocation, pre-booking 3–4 months ahead of the September berry window is the standard procurement pattern. The 2024 Polish frost event reinforced single-region weather variability as the dominant supply-side risk; dual-sourcing Polish base supply with Carpathian wildcraft is the practical hedge.